SM
REGN icon

STF Management’s Regeneron Pharmaceuticals REGN Stock Holding History

STF Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$407K Sell
527
-556
-51% -$378K 0.38% 52
2025
Q3 		$609K Sell
1,083
-6
-0.6% -$3.39K 0.23% 82
2025
Q2 		$572K Buy
1,089
+42
+4% +$23.4K 0.23% 85
2025
Q1 		$664K Buy
1,047
+79
+8% +$54.3K 0.32% 71
2024
Q4 		$690K Sell
968
-589
-38% -$494K 0.31% 70
2024
Q3 		$1.64M Sell
1,557
-157
-9% -$175K 0.74% 32
2024
Q2 		$1.8M Sell
1,714
-75
-4% -$72.7K 0.76% 31
2024
Q1 		$1.72M Sell
1,789
-37
-2% -$35.2K 0.75% 32
2023
Q4 		$1.6M Buy
1,826
+72
+4% +$59.3K 0.75% 36
2023
Q3 		$1.44M Buy
1,754
+1,077
+159% +$846K 0.77% 32
2023
Q2 		$486K Sell
677
-544
-45% -$419K 0.52% 34
2023
Q1 		$1M Buy
1,221
+506
+71% +$382K 0.68% 31
2022
Q4 		$516K Buy
+715
New +$528K 0.74% 33

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

STF Management's REGN Position: Q4 2025 in Review

STF Management reduced its Regeneron Pharmaceuticals (REGN) stake by 51% in Q4 2025, selling an estimated $378K and leaving 527 shares worth $407K. The position accounts for 0.38% of the portfolio, ranked #52.

STF Management first reported a position in REGN in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.8M in Q2 2024. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • STF Management held 527 shares of Regeneron Pharmaceuticals worth $407K as of Q4 2025.
  • STF Management sold 556 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $378K.
  • Regeneron Pharmaceuticals made up 0.38% of STF Management's portfolio in Q4 2025, its #52 holding.
  • STF Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • STF Management's Regeneron Pharmaceuticals position peaked at $1.8M in Q2 2024.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on STF Management's 13F filing for Q4 2025, filed 5 Feb 2026.